Cystic Fibrosis Therapeutics Market Size & Share | Analysis 2034

Cystic Fibrosis Therapeutics Market - By Type, By Age Group, - Global Forecast, 2025 – 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&deg; synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing incidence rate of cystic fibrosis patient population

3.2.1.2&nbsp;&nbsp;&nbsp; Advancements in CFTR modulator therapy

3.2.1.3&nbsp;&nbsp;&nbsp; Growing investment in research and development

3.2.1.4&nbsp;&nbsp;&nbsp; Government support and initiatives

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High treatment costs

3.2.2.2&nbsp;&nbsp;&nbsp; Adverse side effects of current therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Epidemology scenario

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Future market trends

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2021 &ndash; 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Medication

5.2.1&nbsp;&nbsp;&nbsp; Drug class

5.2.1.1&nbsp;&nbsp;&nbsp; CFTR modulators

5.2.1.2&nbsp;&nbsp;&nbsp; Mucolytic agents

5.2.1.3&nbsp;&nbsp;&nbsp; Bronchodilators

5.2.1.4&nbsp;&nbsp;&nbsp; Anti-infective agents

5.2.1.5&nbsp;&nbsp;&nbsp; Pancreatic enzyme supplements

5.2.1.6&nbsp;&nbsp;&nbsp; Other drug classes

5.2.2&nbsp;&nbsp;&nbsp; Route of administration

5.2.2.1&nbsp;&nbsp;&nbsp; Oral

5.2.2.2&nbsp;&nbsp;&nbsp; Inhalation

5.2.3&nbsp;&nbsp;&nbsp; Distribution channel

5.2.3.1&nbsp;&nbsp;&nbsp; Hospital pharmacies

5.2.3.2&nbsp;&nbsp;&nbsp; Retail pharmacies

5.2.3.3&nbsp;&nbsp;&nbsp; Online pharmacies

5.3&nbsp;&nbsp;&nbsp; Non-medication

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 &ndash; 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Below 18 years

6.3&nbsp;&nbsp;&nbsp; 18 - 40 years

6.4&nbsp;&nbsp;&nbsp; 41 and above

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; North America

7.2.1&nbsp;&nbsp;&nbsp; U.S.

7.2.2&nbsp;&nbsp;&nbsp; Canada

7.3&nbsp;&nbsp;&nbsp; Europe

7.3.1&nbsp;&nbsp;&nbsp; Germany

7.3.2&nbsp;&nbsp;&nbsp; UK

7.3.3&nbsp;&nbsp;&nbsp; Ireland

7.4&nbsp;&nbsp;&nbsp; Asia Pacific

7.4.1&nbsp;&nbsp;&nbsp; India

7.4.2&nbsp;&nbsp;&nbsp; Japan

7.4.3&nbsp;&nbsp;&nbsp; Australia

7.5&nbsp;&nbsp;&nbsp; Latin America

7.5.1&nbsp;&nbsp;&nbsp; Brazil

7.5.2&nbsp;&nbsp;&nbsp; Mexico

7.5.3&nbsp;&nbsp;&nbsp; Argentina

7.6&nbsp;&nbsp;&nbsp; Middle East and Africa

7.6.1&nbsp;&nbsp;&nbsp; South Africa

7.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

7.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 8&nbsp;&nbsp;&nbsp;Company Profiles

8.1&nbsp;&nbsp;&nbsp; Alcresta Therapeutics

8.2&nbsp;&nbsp;&nbsp; Baxter

8.3&nbsp;&nbsp;&nbsp; Chiesi Farmaceutici S.p.A.

8.4&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche

8.5&nbsp;&nbsp;&nbsp; Gilead

8.6&nbsp;&nbsp;&nbsp; Koninklijke Philips N.V.

8.7&nbsp;&nbsp;&nbsp; Lupin

8.8&nbsp;&nbsp;&nbsp; Monaghan Medical

8.9&nbsp;&nbsp;&nbsp; Novartis AG

8.10&nbsp;&nbsp;&nbsp; Savara

8.11&nbsp;&nbsp;&nbsp; Sionna Therapeutics

8.12&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries

8.13&nbsp;&nbsp;&nbsp; Vertex Pharmaceuticals

&nbsp;&nbsp;&nbsp;

Cystic Fibrosis Therapeutics Market

Request Discount

Industries

Information

Link

Global Headquarters